Budesonide: Clinical Trials

406 trials of Budesonide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

288 completed, 46 unknown, 23 terminated, 18 recruiting. 140 Phase 3, 92 Phase 4, 76 Phase 2, 57 Phase 1, 40 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 3140Completed 111, Unknown 10, Recruiting 5, Terminated 5, Withdrawn 4, Active not recruiting 3, Enrolling by invitation 1, Suspended 1
Phase 492Completed 57, Unknown 15, Recruiting 7, Terminated 6, Withdrawn 5, Active not recruiting 2
Phase 276Completed 51, Terminated 10, Unknown 4, Withdrawn 4, Active not recruiting 3, Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1
Phase 157Completed 48, Unknown 4, Terminated 3, Active not recruiting 1, Not yet recruiting 1
Not applicable40Completed 19, Unknown 12, Not yet recruiting 3, Recruiting 2, Terminated 2, Withdrawn 2
Early Phase 15Completed 3, Unknown 1, Withdrawn 1

Follow Budesonide: new trials by email Literature Review of Budesonide trials Research Report on Budesonide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Little Lungs Study
Calfactant, Budesonide - Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Phase 1 / Phase 2Not yet recruitingUniversity of Wisconsin, Madison242027-02-012026-11-02
Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler - Asthma, Uncontrolled Asthma
Not yet recruitingAstraZeneca2002027-01-292026-11-12
Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma
Phase 3WithdrawnEurofarma Laboratorios S.A.2026-10-012026-10-23
Inflammatory Profiles, Histopathological Features, and Remodeling Factors in Chronic Rhinosinusitis With Nasal Polyps
Budesonide - CRSwNP, Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis
Not applicableNot yet recruitingSt. Paul's Sinus Centre102026-07-012026-04-14
Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillation
Local Anesthesia With Conscious Sedation, General Anesthesia, VARIPULSE Pulsed Field Ablation System - Paroxysmal Atrial Fibrillation
Not applicableRecruitingChina National Center for Cardiovascular Diseases3902026-06-012026-10-26
An Exploratory Study on Triple Inhaler Therapy in Patients With Early Lung Function Impairment
Budesonide/glycopyrronium bromide/formoterol inhalation aerosol - Preserved Ratio Impaired Spirometry (PRISM)
Not applicableNot yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University232026-06-012026-05-19
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI - Asthma
Phase 1CompletedAstraZeneca162026-03-052026-07-15
Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome
Modified Shenling Baizhu Powder, Placebo, Budesonide and Formoterol Fumarate Powder for Inhalation - Allergic Asthma
Not applicableNot yet recruitingHenan University of Traditional Chinese Medicine4002026-01-152026-01-20
Efficacy of Nebulised Inhalational Steroids in Neonates With Meconium Aspiration Syndrome
Budesonide, Normal Saline - Meconium Aspiration Syndrome
Phase 3CompletedKhyber Teaching Hospital602025-11-282026-08-13
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, Metered dose inhaler - Chronic Obstructive Pulmonary Disease, Hyperinflation
Phase 4RecruitingAstraZeneca562025-11-242026-09-18
Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma
Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma
Phase 2CompletedShanghai Xin Huanghe Pharmaceutical Co., Ltd.1502025-11-212026-09-08
Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study
Budesonide/Glycopyrronium/Formoterol (BGF), Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) - COPD, Chronic Obstructive Pulmonary Disease (COPD)
Phase 4CompletedThammasat University222025-04-012026-02-02
Early Screening of Young COPD and Pre-COPD
Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol - Pulmonary Disease, Chronic Obstructive
Not yet recruitingyanmengkang1002025-03-012025-02-25
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
Budesonide - Chronic Obstructive Pulmonary Disease
Phase 4RecruitingMaria Joyera Rodríguez1352025-02-122026-07-20
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA - Healthy Participants
Phase 1CompletedAstraZeneca1052025-01-232025-06-05
Pharmacokinetics and Bioequivalence Study of Budesonide Inhalation Aerosol in Humans
Budiair® 200ug/puff inhalation aerosol, budesonide 200ug/puff inhalation aerosol - Bioequivalence Study in Healthy Subjects
Not applicableCompletedLunan Better Pharmaceutical Co., LTD.322024-12-302025-04-11
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
TARPEYO® - IgA Nephropathy
Phase 4Active not recruitingCalliditas Therapeutics AB602024-12-172026-09-24
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo - Asthma
Phase 2Active not recruitingSanofi5562024-11-072026-09-22
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
Budesonide-Formoterol treatment - Cough-Variant Asthma
Phase 4CompletedAstraZeneca10002024-10-182025-09-18
Nasal Obstruction With Oxymetazoline and Corticosteroids
Oxymetazoline Nasal Spray, Budesonide nasal spray - Nasal Obstruction
Phase 2RecruitingWashington University School of Medicine802024-10-152025-09-11

Showing 20 of 406. Sign in to see all of them.

Conditions studied

Asthma (167)  ·  Pulmonary Disease, Chronic Obstructive (64)  ·  Eosinophilic Esophagitis (12)  ·  Bronchopulmonary Dysplasia (11)  ·  Crohn Disease (11)  ·  Colitis, Ulcerative (10)  ·  Respiratory Distress Syndrome (9)  ·  Rhinitis, Allergic (9)  ·  Respiratory Sounds (8)  ·  Premature Birth (7)  ·  Disease (6)  ·  Nasal Polyps (6)  ·  Sinusitis (6)  ·  COVID-19 (5)  ·  Rhinitis, Allergic, Seasonal (5)

Sponsors

AstraZeneca (88)  ·  Dr. Falk Pharma GmbH (16)  ·  Orion Corporation, Orion Pharma (12)  ·  Intech Biopharm Ltd. (6)  ·  Mayo Clinic (6)  ·  Bausch Health Americas, Inc. (5)  ·  Beijing Tongren Hospital (5)  ·  Chiesi Farmaceutici S.p.A. (5)  ·  Pearl Therapeutics, Inc. (5)  ·  Bond Avillion 2 Development LP (4)  ·  Eurofarma Laboratorios S.A. (4)  ·  GlaxoSmithKline (4)  ·  Medical University of Lodz (4)  ·  St. Paul's Hospital, Canada (4)  ·  Zhujiang Hospital (4)

Countries

United States (113)  ·  Germany (49)  ·  China (40)  ·  Canada (37)  ·  United Kingdom (32)  ·  Poland (25)  ·  Denmark (17)  ·  Italy (17)  ·  Spain (17)  ·  Brazil (16)  ·  France (16)  ·  Sweden (15)  ·  Hungary (14)  ·  Mexico (13)  ·  Argentina (12)

Top investigators

Catherine Bonuccelli (9)  ·  Bertil Andersson (7)  ·  Christer Hultquist, MD (4)  ·  Frank Albers, MD, PhD (4)  ·  Tomas Andersson, MD (4)  ·  Kimmo Ingman, MD, PhD (3)  ·  Ralph Mueller, PhD (3)  ·  Stephan Miehlke, Prof. (3)  ·  Ulla Sairanen, MSc (3)  ·  Alberto Papi, MD (2)

Results publications

PMID 22329608, PMID 25670896, PMID 29331313, PMID 36472162, PMID 42551404, PMID 19897551, PMID 19995138, PMID 20600032, PMID 22383665, PMID 25644096, PMID 26351971, PMID 27416045, PMID 27912982, PMID 28069068, PMID 28420280, PMID 32738928, PMID 33152467, PMID 33548020, PMID 35815359, PMID 41677208, PMID 10430726, PMID 10655252, PMID 11401887, PMID 11491153, PMID 11549531, PMID 12204862, PMID 12570114, PMID 15591470, PMID 15764724, PMID 15764761, PMID 16055882, PMID 16135736, PMID 16164444, PMID 16650970, PMID 16687712, PMID 17046300, PMID 17107988, PMID 17148626, PMID 17296644, PMID 17905575, PMID 17931847, PMID 18216054, PMID 18295023, PMID 18426851, PMID 18486661, PMID 18550609, PMID 18595959, PMID 18951618, PMID 18958997, PMID 18972276

NIH funding

2015 (4), 2008 (3), 2014 (3), 2016 (3), 2018 (3), U10HL064287 (3), U10HL064288 (3), U10HL064295 (3), U10HL064305 (3), U10HL064307 (3), U10HL064313 (3), 2023 (2), UL1RR024150 (2), 1UG3HL141722-01A1 (1), 2004 (1)